[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60316538D1 - Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen - Google Patents

Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen

Info

Publication number
DE60316538D1
DE60316538D1 DE60316538T DE60316538T DE60316538D1 DE 60316538 D1 DE60316538 D1 DE 60316538D1 DE 60316538 T DE60316538 T DE 60316538T DE 60316538 T DE60316538 T DE 60316538T DE 60316538 D1 DE60316538 D1 DE 60316538D1
Authority
DE
Germany
Prior art keywords
dihydrobenzodiazepine
derivative
treatment
neurological illnesses
illnesses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60316538T
Other languages
English (en)
Other versions
DE60316538T2 (de
Inventor
Geo Adam
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60316538D1 publication Critical patent/DE60316538D1/de
Application granted granted Critical
Publication of DE60316538T2 publication Critical patent/DE60316538T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DE60316538T 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen Expired - Lifetime DE60316538T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06
EP02002012 2002-02-06
PCT/EP2003/000859 WO2003066623A1 (en) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
DE60316538D1 true DE60316538D1 (de) 2007-11-08
DE60316538T2 DE60316538T2 (de) 2008-08-21

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316538T Expired - Lifetime DE60316538T2 (de) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen

Country Status (31)

Country Link
US (1) US6949542B2 (de)
EP (1) EP1474416B1 (de)
JP (1) JP4077411B2 (de)
KR (1) KR20040081486A (de)
CN (1) CN100497333C (de)
AR (1) AR038481A1 (de)
AT (1) ATE374196T1 (de)
AU (1) AU2003205695B8 (de)
BR (1) BR0307474A (de)
CA (1) CA2474219C (de)
DE (1) DE60316538T2 (de)
DK (1) DK1474416T3 (de)
ES (1) ES2294264T3 (de)
GT (1) GT200300028A (de)
HK (1) HK1078858A1 (de)
HR (1) HRP20040678A2 (de)
IL (1) IL163102A (de)
MX (1) MXPA04007516A (de)
MY (1) MY176608A (de)
NO (1) NO327697B1 (de)
NZ (1) NZ534122A (de)
PA (1) PA8565901A1 (de)
PE (1) PE20031011A1 (de)
PL (1) PL372425A1 (de)
PT (1) PT1474416E (de)
RU (1) RU2315764C2 (de)
SI (1) SI1474416T1 (de)
TW (1) TWI326599B (de)
UY (1) UY27654A1 (de)
WO (1) WO2003066623A1 (de)
ZA (1) ZA200406032B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029012A2 (en) 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
KR100764330B1 (ko) * 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한mGluR2 길항제 및 AChE 억제제의 조합물
EP1934214B1 (de) 2005-09-27 2010-04-07 F.Hoffmann-La Roche Ag Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ES2369866T3 (es) * 2007-04-19 2011-12-07 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida.
CN102083799B (zh) 2007-08-27 2013-10-16 霍夫曼-拉罗奇有限公司 用作fxr激动剂的苯并咪唑衍生物
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
DK2203439T3 (da) 2007-09-14 2011-04-18 Ortho Mcneil Janssen Pharm 1',3'-disubstituerede 4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']-bipyridinyl-2'-oner
CA2698929C (en) 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2732806A1 (en) 2008-08-04 2010-02-11 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
EP2346505B1 (de) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indol- und benzomorpholinderivate als modulatoren von metabotropen glutamatrezeptoren
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
CA2771136A1 (en) 2009-08-21 2011-02-24 Otsuka Pharmaceutical Co., Ltd. Process for producing benzo[b][1,4]diazepine-2,4-dione compound
WO2011091153A1 (en) 2010-01-25 2011-07-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
EP2751095B1 (de) * 2011-08-29 2021-10-27 Sanford-Burnham Medical Research Institute Neue benzodiazepinone als modulatoren der metabotropen glutamatrezeptorfunktionen und neurologische verwendungen davon
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2880117C (en) 2012-07-27 2021-04-06 The Broad Institute, Inc. Inhibitors of histone deacetylase
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2748633T3 (es) 2014-01-21 2020-03-17 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
RU2016144702A (ru) 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
JP6552061B2 (ja) * 2014-06-10 2019-07-31 サンフォード−バーンハム メディカル リサーチ インスティテュート 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用
EP3169684B1 (de) 2014-07-17 2019-06-26 CHDI Foundation, Inc. Kombination des kmo inhibitors 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carbonsäure mit antiviralem wirkstoff zur behandlung von mit hiv zusammenhängenden neurologischen erkrankungen
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN112135610A (zh) 2018-01-12 2020-12-25 KDAc治疗股份有限公司 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008906T2 (de) * 1989-03-23 1994-08-25 Pfizer Antiallergische Mittel auf der Basis von Diazepin.
WO2001029012A2 (en) 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
DK1224174T3 (da) 1999-10-15 2004-01-26 Hoffmann La Roche Benzodiazepinderivater

Also Published As

Publication number Publication date
RU2004126945A (ru) 2005-06-27
ES2294264T3 (es) 2008-04-01
NO20043237L (no) 2004-08-02
PT1474416E (pt) 2007-12-27
US6949542B2 (en) 2005-09-27
EP1474416B1 (de) 2007-09-26
GT200300028A (es) 2004-06-11
MY176608A (en) 2020-08-18
IL163102A (en) 2011-07-31
NZ534122A (en) 2006-12-22
AR038481A1 (es) 2005-01-19
HRP20040678A2 (en) 2005-10-31
UY27654A1 (es) 2003-08-29
BR0307474A (pt) 2004-11-09
PA8565901A1 (es) 2003-09-05
PE20031011A1 (es) 2003-11-29
ZA200406032B (en) 2005-10-12
MXPA04007516A (es) 2004-11-10
EP1474416A1 (de) 2004-11-10
PL372425A1 (en) 2005-07-25
AU2003205695B8 (en) 2008-05-01
WO2003066623A1 (en) 2003-08-14
NO327697B1 (no) 2009-09-14
CA2474219A1 (en) 2003-08-14
DE60316538T2 (de) 2008-08-21
KR20040081486A (ko) 2004-09-21
JP2005522440A (ja) 2005-07-28
AU2003205695B2 (en) 2008-04-03
CN100497333C (zh) 2009-06-10
TW200302730A (en) 2003-08-16
DK1474416T3 (da) 2008-01-14
HK1078858A1 (en) 2006-03-24
CA2474219C (en) 2010-04-13
SI1474416T1 (sl) 2008-02-29
CN1633430A (zh) 2005-06-29
US20030166639A1 (en) 2003-09-04
ATE374196T1 (de) 2007-10-15
TWI326599B (en) 2010-07-01
JP4077411B2 (ja) 2008-04-16
AU2003205695A1 (en) 2003-09-02
RU2315764C2 (ru) 2008-01-27

Similar Documents

Publication Publication Date Title
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE439844T1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE372674T1 (de) N-arylhydrazonderivate für die saatgutbehandlung
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE515266T1 (de) 2-(amino-3,4-dioxo-1-cyclobuten-1- yl)aminoalkylsäure-derivate für die schmerzbehandlung
ATE369136T1 (de) Therapeutische behandlung
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
ATE357441T1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne
ATE253556T1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition